Screen Shot 2023 09 06 At 11 17 20 Am

Bridging the gap between R&D and GMP

Companies prioritizing optimized synthetic routes, stable API forms, and verified analytical tools set the stage for phase I clinical manufacturing success
Shutterstock 1907619631

Optimizing mRNA therapeutics

Novel techniques for mRNA delivery, capping and more will be key to producing more effective vaccines
Shutterstock 1664112631

Meeting biopharma’s infrastructure demands

Biopharma facilities must address the specific needs and concerns of this dynamic sector
Shutterstock 2224667693

OSD spreads its wings

Bright ideas are helping drugs and butterflies take flight
Microsoft Teams Image (1)

OSD soars: Evolution of oral solid dose technology

In phase 2 of our OSD series, we cover the resurgence of fixed-dose combinations and the pursuit of effective oral delivery for biologics
Microsoft Teams Image (2)

OSD soars: The digital metamorphosis

In phase III of our OSD series, we cover what's on the horizon for the digital metamorphosis of drug delivery, including 3D printing and robot pills.

Surrendering to the pharma magic

The science of ADCs makes for an incredible show
How Mass Spectrometer Works

Mass spectrometry: Optimizing biopharma manufacturing

Speed and precision make MS the first choice for the real-time monitoring of fermentation and cell culture off-gas
Screen Shot 2023 06 14 At 12 13 06 Pm

Spring pharma happenings: PDA’s Annual Meeting 2023

Through discussions that focused on innovative operational approaches as well as powerful patient-hosted sessions, the show sought to remind manufacturers to keep a patient-focused...
Pm22 Hero 854x480 Act1 Cover Story

The great reappearing act: ADCs' triumphant return

In our three-part series, we cover the trajectory of cancer-fighting ADCs in the pharma industry, including the modality’s history, obstacles and success stories
Microsoft Teams Image (1)

The great reappearing act: ADCs light up the stage

In the third and final part of our series on antibody-drug conjugates, we discuss the recent market buzz and the rise of new conjugated modalities.
Pm22 Hero 854x480 Act2 Cover Story

The great reappearing act: ADCs' new bag of tricks

In Act 2 of our series on antibody-drug conjugates, we cover improved linker and payload technology
Pm22 Hero 854x480 Web

Assuring generic access evermore

Generics’ longevity hinges on steady, straightforward storytelling
Shutterstock 1978782344

Beyond empty and full

The field is in need of more detailed product understanding to increase product safety without sacrificing efficacy
Screen Shot 2023 03 09 At 1 46 33 Pm

The next chapter in cell and gene therapy

ATW 2023 celebrated a record-breaking year of approvals, with an eye on new realities